TRPV2 and non-small cell lung carcinoma: VRL induces metaphase arrest in dividing cells, disrupting the microtubules [14], and it has been approved for the treatment of non-small-cell lung cancer (NSCLC) in humans, either as a single agent or in polychemotherapy regimens [15].